Pfizer-BioNTech begin global study of lead COVID-19 vaccine candidate


(Reuters) – German biotech BioNTech and U.S. drugmaker Pfizer Inc said on Monday they would begin a global study to evaluate their lead COVID-19 vaccine candidate.


The mid-stage study is expected to include about 120 sites globally.

(Reporting by Vishwadha Chander in Bengaluru; Editing by Maju Samuel)

Source link


Articles You May Like

Aid group ACTED says its staff members caught up in Niger attack
Police clash with protesters in Belarusian capital – Reuters witness
Nine babies dumped every month
El Salvador supreme court rebukes president’s decree to reopen economy
UK says progress made on Brexit; EU trade deal can be done